CY1108841T1 - Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2 - Google Patents

Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2

Info

Publication number: CY1108841T1
Authority: CY; Cyprus
Prior art keywords: prostaglandin; cycloalkanoidoles; receptor antagonists; fluorine substituted; fluorine
Prior art date: 2002-01-24

Application number

CY20091100147T

Other languages

Greek (el)

English (en)

Inventor

Carl Berthelette

Nicolas Lachance

Lianhai Li

Claudio Sturino

Zhaoyin Wang

Original Assignee

Merck Frosst Canada Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-24

Filing date

2009-02-09

Publication date

2011-04-06

2009-02-09 Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.

2011-04-06 Publication of CY1108841T1 publication Critical patent/CY1108841T1/el

Links

PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 title 1
102000009389 Prostaglandin D receptors Human genes 0.000 title 1
108050000258 Prostaglandin D receptors Proteins 0.000 title 1
229910052731 fluorine Inorganic materials 0.000 title 1
239000011737 fluorine Substances 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
-1 2,4,6-trichlorophenyl Chemical group 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
239000002089 prostaglandin antagonist Substances 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)

CY20091100147T 2002-01-24 2009-02-09 Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2 CY1108841T1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35138402P	2002-01-24	2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en)	2002-01-24	2003-01-22	Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number	Publication Date
CY1108841T1 true CY1108841T1 (el)	2011-04-06

Family

ID=27613492

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20091100147T CY1108841T1 (el)	2002-01-24	2009-02-09	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
CY200900004C CY2009004I2 (el)	2002-01-24	2009-03-31	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
CY20121100844T CY1113330T1 (el)	2002-01-24	2012-09-17	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY200900004C CY2009004I2 (el)	2002-01-24	2009-03-31	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
CY20121100844T CY1113330T1 (el)	2002-01-24	2012-09-17	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2

Country Status (39)

Country	Link
US (6)	US20030158246A1 (2)
EP (3)	EP2045241B1 (2)
JP (2)	JP4008885B2 (2)
KR (2)	KR100859230B1 (2)
CN (3)	CN101092388A (2)
AR (1)	AR038136A1 (2)
AT (1)	ATE414690T1 (2)
AU (1)	AU2003202343B2 (2)
BR (1)	BR0307050A (2)
CA (1)	CA2471952C (2)
CY (3)	CY1108841T1 (2)
DE (2)	DE60324767D1 (2)
DK (2)	DK1470107T3 (2)
DO (1)	DOP2003000566A (2)
EA (1)	EA006134B1 (2)
EC (1)	ECSP045203A (2)
EG (1)	EG24978A (2)
ES (2)	ES2316717T3 (2)
FR (1)	FR09C0010I2 (2)
GE (1)	GEP20074078B (2)
HR (1)	HRP20040665B1 (2)
IL (3)	IL162825A0 (2)
IS (2)	IS2633B (2)
JO (1)	JO2481B1 (2)
LU (1)	LU91534I2 (2)
MX (1)	MXPA04007167A (2)
MY (1)	MY137040A (2)
NL (1)	NL300377I2 (2)
NO (3)	NO327322B1 (2)
NZ (1)	NZ533786A (2)
PE (1)	PE20030982A1 (2)
PL (1)	PL208527B1 (2)
PT (2)	PT2045241E (2)
RS (2)	RS51672B (2)
SI (2)	SI1470107T1 (2)
TW (1)	TWI259080B (2)
UA (1)	UA75520C2 (2)
WO (1)	WO2003062200A2 (2)
ZA (1)	ZA200404999B (2)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) *	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
US20070054951A1 (en) *	2003-05-20	2007-03-08	Lianhai Li	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
AU2004262970B2 (en) *	2003-08-07	2010-03-18	Merck Sharp & Dohme Limited	Treatment for Alzheimer's disease and related conditions
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
JP5239071B2 (ja) *	2004-04-02	2013-07-17	メルク・シャープ・アンド・ドーム・コーポレーション	シクロアルカノインドール誘導体の調製のために有用な非対称水素化方法
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
US20070299122A1 (en) *	2004-11-08	2007-12-27	Tobert Jonathan A	Method of Treating Pathological Blushing
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
JPWO2006068162A1 (ja) *	2004-12-24	2008-06-12	塩野義製薬株式会社	慢性閉塞性肺疾患の治療剤
CA2594280C (en) *	2004-12-27	2013-04-23	Anja Fecher	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
US20080139604A1 (en) *	2005-02-17	2008-06-12	Shaun Fitzpatrick	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AU2006236939A1 (en) *	2005-04-13	2006-10-26	Merck Sharp & Dohme Corp.	Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP2397476A3 (en)	2005-07-22	2011-12-28	Shionogi & Co., Ltd.	Indole derivative having PGD2 receptor antagonist activity
JP5064219B2 (ja)	2005-07-22	2012-10-31	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP1932839A4 (en)	2005-09-06	2014-09-10	Shionogi & Co	INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
WO2007149312A2 (en)	2006-06-16	2007-12-27	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
ATE530523T1 (de)	2006-08-07	2011-11-15	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
EP2114154B1 (en) *	2007-02-08	2013-08-28	Merck Sharp & Dohme Corp.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
WO2010008864A2 (en)	2008-06-24	2010-01-21	Amira Pharmaceuticals, Inc.	Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
US8507473B2 (en)	2008-09-11	2013-08-13	Arena Pharmaceuticals, Inc.	3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010034110A1 (en) *	2008-09-25	2010-04-01	Merck Frosst Canada Ltd.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) *	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
US8882678B2 (en) *	2009-03-13	2014-11-11	Atrium Medical Corporation	Pleural drainage system and method of use
AR080703A1 (es)	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
DK2697223T3 (en)	2011-04-14	2016-09-05	Actelion Pharmaceuticals Ltd	7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es)	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) *	2012-03-28	2015-01-21	中国计量学院	合成分离拉洛皮兰及其类似物的方法
FR3000399B1 (fr) *	2012-12-31	2015-03-27	Galderma Res & Dev	Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000395A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
PE20161177A1 (es)	2014-03-17	2016-11-18	Actelion Pharmaceuticals Ltd	Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP6770522B2 (ja)	2015-02-13	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태
CN111886315B (zh)	2018-03-19	2023-06-30	三井化学株式会社	显示元件用密封材及其固化物、有机el元件用框密封材以及有机el元件用面密封材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
EP0234708B1 (en)	1986-01-23	1991-02-27	Merck Frosst Canada Inc.	Tetrahydrocarbazole 1-alkanoic acids
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
WO1995015973A1 (en)	1993-12-06	1995-06-15	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en)	1994-07-11	1996-02-09	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (en)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
CN1134411C (zh)	1995-06-21	2004-01-14	盐野义制药株式会社	双环氨基衍生物及含有此类化合物的前列腺素d2拮抗剂
US6034057A (en)	1995-07-06	2000-03-07	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
PL191760B1 (pl)	1996-12-13	2006-06-30	Shionogi & Co	Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
CN1198649C (zh)	1998-06-03	2005-04-27	盐野义制药株式会社	用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active Expired - Fee Related
- 2003-01-22 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Withdrawn
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en not_active Ceased
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 RS YU62404A patent/RS51672B/sr unknown
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/sr unknown
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown

Also Published As

Publication number	Publication date
US20050124680A1 (en)	2005-06-09
KR20040075109A (ko)	2004-08-26
NL300377I1 (nl)	2009-05-06
EP2295409B1 (en)	2014-07-02
ATE414690T1 (de)	2008-12-15
AU2003202343B2 (en)	2007-07-12
IS8887A (is)	2010-03-01
CA2471952A1 (en)	2003-07-31
IS2633B (is)	2010-06-15
ES2391747T3 (es)	2012-11-29
EP2045241A1 (en)	2009-04-08
HRP20040665B1 (en)	2012-11-30
EP1470107B1 (en)	2008-11-19
DE60324767D1 (de)	2009-01-02
US20030158246A1 (en)	2003-08-21
EP2295409A1 (en)	2011-03-16
SI2045241T1 (sl)	2012-11-30
DK1470107T3 (da)	2009-03-09
NO20043536L (no)	2004-08-24
NO2009013I1 (no)	2009-06-29
CN1902176A (zh)	2007-01-24
TWI259080B (en)	2006-08-01
PT1470107E (pt)	2009-01-30
EG24978A (en)	2011-04-03
CY2009004I1 (el)	2009-11-04
CY1113330T1 (el)	2016-06-22
ECSP045203A (es)	2004-09-28
EA200400971A1 (ru)	2004-12-30
IL162825A (en)	2010-12-30
AR038136A1 (es)	2004-12-29
EP2045241B1 (en)	2012-07-04
RS20100338A (sr)	2011-06-30
US20120115921A1 (en)	2012-05-10
FR09C0010I1 (2)	2009-04-17
CN101092388A (zh)	2007-12-26
SI1470107T1 (sl)	2009-04-30
RS51672B (sr)	2011-10-31
EA006134B1 (ru)	2005-10-27
FR09C0010I2 (2)	2009-12-18
KR20070056166A (ko)	2007-05-31
DOP2003000566A (es)	2003-09-15
US20060069148A1 (en)	2006-03-30
IL188844A0 (en)	2009-02-11
JP2005518413A (ja)	2005-06-23
MXPA04007167A (es)	2004-10-29
WO2003062200A3 (en)	2003-12-04
DK2045241T3 (da)	2012-10-15
JP2007186521A (ja)	2007-07-26
BR0307050A (pt)	2004-10-26
PE20030982A1 (es)	2003-11-19
CY2009004I2 (el)	2009-11-04
NL300377I2 (nl)	2009-08-03
CA2471952C (en)	2008-04-01
ZA200404999B (en)	2006-05-31
KR100859230B1 (ko)	2008-09-18
LU91534I2 (fr)	2009-04-27
JP4008885B2 (ja)	2007-11-14
IL162825A0 (en)	2005-11-20
ES2316717T3 (es)	2009-04-16
CN101851191A (zh)	2010-10-06
US20100081696A1 (en)	2010-04-01
RS62404A (sr)	2006-12-15
MY137040A (en)	2008-12-31
UA75520C2 (en)	2006-04-17
PL370427A1 (en)	2005-05-30
AU2003202343C1 (en)	2003-09-02
JO2481B1 (en)	2009-01-20
HRP20040665A2 (en)	2005-04-30
IS7329A (is)	2004-06-21
DE122009000022I1 (de)	2009-08-06
EP1470107A2 (en)	2004-10-27
PL208527B1 (pl)	2011-05-31
TW200302090A (en)	2003-08-01
US7317036B2 (en)	2008-01-08
US7618994B2 (en)	2009-11-17
NO327322B1 (no)	2009-06-08
PT2045241E (pt)	2012-09-26
GEP20074078B (en)	2007-03-26
NO20071193L (no)	2004-08-24
NZ533786A (en)	2006-11-30
NO2009013I2 (no)	2012-08-27
US20080033028A1 (en)	2008-02-07
WO2003062200A2 (en)	2003-07-31

Publication	Publication Date	Title
CY1108841T1 (el)	2011-04-06	Υποκατεστημενες με φθοριο κυκλοαλκανοϊνδολες και η χρηση τους ως ανταγωνιστες των υποδοχεων προσταγλανδινης d2
AR021055A1 (es)	2002-06-12	Derivados de pirazolopiridina
CY1105797T1 (el)	2011-02-02	Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα
CY1112991T1 (el)	2016-04-13	ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ
CY1109656T1 (el)	2014-08-13	Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1109510T1 (el)	2014-08-13	Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων
CY1108378T1 (el)	2014-02-12	4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
ATE302775T1 (de)	2005-09-15	Carbolinderivate
CY1108451T1 (el)	2014-04-09	Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5
CY1108067T1 (el)	2014-02-12	Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105621T1 (el)	2010-12-22	Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
EA200100826A1 (ru)	2002-02-28	16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
CY1106606T1 (el)	2012-01-25	Διϋδροξυπυριμιδινο καρβοξαμιδια αναστολεις της ιντεγκρασης του hiv
UY27918A1 (es)	2003-12-31	Derivados de benzodioxol
ES475677A1 (es)	1979-04-16	Procedimiento para la preparacion de nuevos 4-hidroxi-2h-1,2-benzotiazin-3-carboxamido-1,1-dioxidos.
CY1114241T1 (el)	2016-08-31	Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια
CY1111980T1 (el)	2015-11-04	Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
CY1105047T1 (el)	2009-11-04	Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν
CY1113171T1 (el)	2016-04-13	Αντιφλεγμονωδεις παραγοντες
CY1109129T1 (el)	2014-07-02	Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
CY1109085T1 (el)	2012-05-23	Νεα αλατα
CY1107519T1 (el)	2013-03-13	Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις
AR036649A1 (es)	2004-09-22	Derivados de diarilmetilen piperidina, uso de estos derivados para la manufactura de medicamentos y composicion farmaceutica
AR041898A1 (es)	2005-06-01	Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
AR035247A1 (es)	2004-05-05	Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen